Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs

Behavioural Pharmacology

Volumn 25, Issue 5-6, 2014, Pages 425-433

  Batista, Luara A ^a   Gobira, Pedro H ^a   Viana, Thercia G ^a   Aguiar, Daniele C ^a   Moreira, Fabricio A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

2 arachidonoyl glycerol; anandamide; anxiety; endocannabinoids; fatty acid amide hydrolase; monoacylglycerol lipase

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; ANANDAMIDE; ANXIOLYTIC AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR; CANNABIS; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1;

ANXIETY DISORDER; ARTICLE; BRAIN LEVEL; DRUG MECHANISM; FEAR; HYDROLYSIS; MEMBRANE TRANSPORT; MOTOR ACTIVITY; NEUROANATOMY; NONHUMAN; TRANQUILIZING ACTIVITY; ANIMAL; ANXIETY; BRAIN; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG THERAPY; HUMAN; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BRAIN; DRUG DISCOVERY; ENDOCANNABINOIDS; HUMANS; HYDROLYSIS; NEURONS;

EID: 84906053208     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000073     Document Type: Article

References (113)

1. Albelda N, Joel D (2012). Animal models of obsessive-compulsive disorder: Exploring pharmacology and neural substrates. Neurosci Biobehav Rev 36:47-63.
2. Alger BE, Kim J (2011). Supply and demand for endocannabinoids. Trends Neurosci 34:304-315.
3. Aliczki M, Balogh Z, Tulogdi A, Haller J (2012). The temporal dynamics of the effects of monoacylglycerol lipase blockade on locomotion, anxiety, and body temperature. Behav Pharmacol 23:348-357.
4. Aliczki M, Zelena D, Mikics E, Varga ZK, Pinter O, Bakos NV, et al. (2013). Monoacylglycerol lipase inhibition-induced changes in plasma corticosterone levels, anxiety and locomotor activity in male CD1 mice. Horm Behav 63:752-758.
5. Almeida-Santos AF, Gobira PH, Rosa LC, Guimaraes FS, Moreira FA, Aguiar DC (2013). Modulation of anxiety-like behavior by the endocannabinoid 2-Arachidonoylglycerol (2-AG) in the dorsolateral periaqueductal gray. Behav Brain Res 252:10-17.
6. American Psychiatric Association. 2013 Diagnostic and statistical manual of mental disorders 5th ed. Arlington, VA: American Psychiatric Publishing.
7. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, et al. (2014). Evidence-based pharmacological treatment of anxiety disorders, posttraumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 28:403-439.
8. Basavarajappa BS, Subbanna S (2014). CB1 receptor-mediated signaling underlies the hippocampal synaptic, learning, and memory deficits following treatment with JWH-081, a new component of spice/K2 preparations. Hippocampus 24:178-188.
9. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997). Functional role of high-Affinity anandamide transport, as revealed by selective inhibition. Science 277:1094-1097.
10. Bergamaschi MM, Queiroz RH, Chagas MH, Linares IM, Arrais KC, de Oliveira DC, et al. (2014). Rimonabant effects on anxiety induced by simulated public speaking in healthy humans: A preliminary report. Hum Psychopharmacol 29:94-99.
11. Berrendero F, Maldonado R (2002). Involvement of the opioid system in the anxiolytic-like effects induced by delta(9)-Tetrahydrocannabinol. Psychopharmacology (Berl) 163:111-117.
12. Bitencourt RM, Pamplona FA, Takahashi RN (2008). Facilitation of contextual fear memory extinction and anti-Anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol 18:849-859.
13. Bortolato M, Campolongo P, Mangieri RA, Scattoni ML, Frau R, Trezza V, et al. (2006). Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 31:2652-2659.
14. Braida D, Limonta V, Malabarba L, Zani A, Sala M (2007). 5-HT1A receptors are involved in the anxiolytic effect of Delta9-Tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur J Pharmacol 555:156-163.
15. Busquets-Garcia A, Puighermanal E, Pastor A, De La Torre R, Maldonado R, Ozaita A (2011). Differential role of anandamide and 2-Arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70:479-486.
16. Campolongo P, Ratano P, Manduca A, Scattoni ML, Palmery M, Trezza V, Cuomo V (2012). The endocannabinoid transport inhibitor AM404 differentially modulates recognition memory in rats depending on environmental aversiveness. Front Behav Neurosci 6:11.
17. Campos AC, Ferreira FR, Guimarães FS, Lemos JI (2010). Facilitation of endocannabinoid effects in the ventral hippocampus modulates anxiety-like behaviors depending on previous stress experience. Neuroscience 167:238-246.
18. Casarotto PC, Terzian AL, Aguiar DC, Zangrossi H, Guimarães FS, Wotjak CT, Wotjak CT (2012). Opposing roles for cannabinoid receptor type-1 (CB1) and transient receptor potential vanilloid type-1 channel (TRPV1) on the modulation of panic-like responses in rats. Neuropsychopharmacology 37: 478-486.
19. Castillo PE, Younts TJ, Chávez AE, Hashimotodani Y (2012). Endocannabinoid signaling and synaptic function. Neuron 76:70-81.
20. Chhatwal JP, Davis M, Maguschak KA, Ressler KJ (2005). Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 30:516-524.
21. Compton DR, Johnson MR, Melvin LS, Martin BR (1992). Pharmacological profile of a series of bicyclic cannabinoid analogs: Classification as cannabimimetic agents. J Pharmacol Exp Ther 260:201-209.
22. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996). Molecular characterization of an enzyme that degrades neuromodulatory fattyacid amides. Nature 384:83-87.
23. De Carvalho CR, Pamplona FA, Cruz JS, Takahashi RN (2014). Endocannabinoids underlie reconsolidation of hedonic memories in Wistar rats. Psychopharmacology (Berl) 231:1417-1425.
24. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613.
25. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
26. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 99:10819-10824.
27. Dissanayake DW, Mason R, Marsden CA (2013). Sensory gating, cannabinoids and schizophrenia. Neuropharmacology 67:66-77.
28. Fabre LF, McLendon D (1981). The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol 21:377S-382S.
29. File SE, Lippa AS, Beer B, Lippa MT (2004). Animal tests of anxiety. Curr Protoc Neurosci 8:8.3.
30. Finn DP (2010). Endocannabinoid-mediated modulation of stress responses: Physiological and pathophysiological significance. Immunobiology 215: 629-646.
31. Finn DP, Jhaveri MD, Beckett SR, Roe CH, Kendall DA, Marsden CA, Chapman V (2003). Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 45:594-604.
32. Fowler CJ (2013). Transport of endocannabinoids across the plasma membrane and within the cell. FEBS J 280:1895-1904.
33. Fraser GA (2009). The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 15:84-88.
34. Fride E, Mechoulam R (1993). Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 231: 313-314.
35. García-Gutiérrez MS, Ortega-Álvaro A, Busquets-Garcia A, Pérez-Ortiz JM, Caltana L, Ricatti MJ, et al. (2013). Synaptic plasticity alterations associated with memory impairment induced by deletion of CB2 cannabinoid receptors. Neuropharmacology 73:388-396.
36. Gobira PH, Aguiar DC, Moreira FA (2013). Effects of compounds that interfere with the endocannabinoid system on behaviors predictive of anxiolytic and panicolytic activities in the elevated T-maze. Pharmacol Biochem Behav 110:33-39.
37. Gomes FV, Casarotto PC, Resstel LB, Guimarães FS (2011). Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice. Prog Neuropsychopharmacol Biol Psychiatry 35:434-438.
38. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, Uhl GR (2006). Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Res 1071:10-23.
39. Goonawardena AV, Sesay J, Sexton CA, Riedel G, Hampson RE (2011). Pharmacological elevation of anandamide impairs short-Term memory by altering the neurophysiology in the hippocampus. Neuropharmacology 61:1016-1025.
40. Gorzalka BB, Hill MN, Hillard CJ (2008). Regulation of endocannabinoid signaling by stress: Implications for stress-related affective disorders. Neurosci Biobehav Rev 32:1152-1160.
41. Gregg LC, Jung KM, Spradley JM, Nyilas R, Suplita RL 2nd, Zimmer A, et al. (2012). Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-a initiates 2-Arachidonoylglycerol formation and endocannabinoidmediated analgesia. J Neurosci 32:9457-9468.
42. Griebel G, Holmes A (2013). 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 12:667-687.
43. Gunduz-Cinar O, Hill MN, McEwen BS, Holmes A (2013). Amygdala FAAH and anandamide: Mediating protection and recovery from stress. Trends Pharmacol Sci 34:637-644.
44. Hakimizadeh E, Oryan S, Hajizadeh Moghaddam A, Shamsizadeh A, Roohbakhsh A (2012). Endocannabinoid system and TRPV1 receptors in the dorsal hippocampus of the rats modulate anxiety-like behaviors. Iran J Basic Med Sci 15:795-802.
45. Hall W, Solowij N (1998). Adverse effects of cannabis. Lancet 352:1611-1616.
46. Haller J, Varga B, Ledent C, Barna I, Freund TF (2004). Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 19:1906-1912.
47. Haller J, Barna I, Barsvari B, Gyimesi Pelczer K, Yasar S, Panlilio LV, Goldberg S (2009). Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl) 204:607-616.
48. Hansson AC, Bermúdez-Silva FJ, Malinen H, Hyytiä P, Sanchez-Vera I, Rimondini R, et al. (2007). Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology 32:117-126.
49. Hermanson DJ, Hartley ND, Gamble-George J, Brown N, Shonesy BC, Kingsley PJ, et al. (2013). Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nat Neurosci 16:1291-1298.
50. Hill MN, Karacabeyli ES, Gorzalka BB (2007). Estrogen recruits the endocannabinoid system to modulate emotionality. Psychoneuroendocrinology 32:350-357.
51. Hill MN, Hillard CJ, Bambico FR, Patel S, Gorzalka BB, Gobbi G (2009). The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci 30:484-493.
52. Högestätt ED, Jönsson BA, Ermund A, Andersson DA, Björk H, Alexander JP, et al. (2005). Conversion of acetaminophen to the bioactive N-Acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 280: 31405-31412.
53. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435:1108-1112.
54. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. (2002). International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
55. Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA (2001). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 58:322-328.
56. John CS, Currie PJ (2012). N-Arachidonoyl-serotonin in the basolateral amygdale increases anxiolytic behavior in the elevated plus maze. Behav Brain Res 233:382-388.
57. Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, et al. (2008). Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry 64:930-937.
58. Kalant H (2004). Adverse effects of cannabis on health: An update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 28:849-863.
59. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81.
60. Kawahara H, Drew GM, Christie MJ, Vaughan CW (2011). Inhibition of fatty acid amide hydrolase unmasks CB1 receptor and TRPV1 channel-mediated modulation of glutamatergic synaptic transmission in midbrain periaqueductal grey. Br J Pharmacol 163:1214-1222.
61. Kessler RC, Ruscio AM, Shear K, Wittchen HU (2010). Epidemiology of anxiety disorders. Curr Top Behav Neurosci 2:21-35.
62. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH (2011). Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. Pharmacol Biochem Behav 98:21-27.
63. Lisboa SF, Resstel LB, Aguiar DC, Guimarães FS (2008). Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. Eur J Pharmacol 593:73-78.
64. Lisboa SF, Reis DG, Da Silva AL, Corrêa FM, Guimarães FS, Resstel LB (2010). Cannabinoid CB1 receptors in the medial prefrontal cortex modulate the expression of contextual fear conditioning. Int J Neuropsychopharmacol 13:1163-1173.
65. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, et al. (2009). Selective blockade of 2-Arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5:37-44.
66. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, et al. (2009). Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci USA 106:20270-20275.
67. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, et al. (1991). Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40:471-478.
68. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O (2002). Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159:379-387.
69. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564.
70. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90.
71. Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F, Di Marzo V (2009). Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 34:593-606.
72. Moise AM, Eisenstein SA, Astarita G, Piomelli D, Hohmann AG (2008). An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology (Berl) 200:333-346.
73. Moreira FA, Crippa JA (2009). The psychiatric side-effects of rimonabant. Rev Bras Psiquiatr 31:145-153.
74. Moreira FA, Aguiar DC, Guimarães FS (2007). Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 52:958-965.
75. Moreira FA, Kaiser N, Monory K, Lutz B (2008). Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoiddegrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 54:141-150.
76. Moreira FA, Aguiar DC, Resstel LB, Lisboa SF, Campos AC, Gomes FV, Guimarães FS (2012). Neuroanatomical substrates involved in cannabinoid modulation of defensive responses. J Psychopharmacol 26:40-55.
77. Moreira FA, Aguiar DC, Terzian AL, Guimarãe FS, Wotjak CT (2012). Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety-Two sides of one coin? Neuroscience 204:186-192.
78. Moreira FA, Gobira PH, Viana TG, Vicente MA, Zangrossi H, Graeff FG (2013). Modeling panic disorder in rodents. Cell Tissue Res 354:119-125.
79. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65.
80. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, Lichtman AH (2007). Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 192:61-70.
81. Navarro M, Hernández E, Muñoz RM, del Arco I, Villanúa MA, Carrera MR, Rodríguez de Fonseca F (1997). Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8:491-496.
82. Onaivi ES, Green MR, Martin BR (1990). Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 253:1002-1009.
83. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, et al. (2006). Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074:514-536.
84. Ortega-Alvaro A, Aracil-Fernández A, García- Gutiérrez MS, Navarrete F, Manzanares J (2011). Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacology 36:1489-1504.
85. Patel S, Hillard CJ (2006). Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: Further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318:304-311.
86. Patel S, Hillard CJ (2008). Adaptations in endocannabinoid signaling in response to repeated homotypic stress: A novel mechanism for stress habituation. Eur J Neurosci 27:2821-2829.
87. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ (2004). Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-Adrenal axis. Endocrinology 145:5431-5438.
88. Pertwee RG (2008). Ligands that target cannabinoid receptors in the brain: From THC to anandamide and beyond. Addict Biol 13:147-159.
89. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. (2010). International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacol Rev 62:588-631.
90. Piomelli D (2003). The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-884.
91. Piomelli D (2014). More surprises lying ahead. The endocannabinoids keep us guessing. Neuropharmacology Pt B:228-234.
92. Puighermanal E, Busquets-Garcia A, Maldonado R, Ozaita A (2012). Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids. Philos Trans R Soc Lond B Biol Sci 367:3254-3263.
93. Resstel LB, Lisboa SF, Aguiar DC, Corrêa FM, Guimarães FS (2008). Activation of CB1 cannabinoid receptors in the dorsolateral periaqueductal gray reduces the expression of contextual fear conditioning in rats. Psychopharmacology (Berl) 198:405-411.
94. Rey AA, Purrio M, Viveros MP, Lutz B (2012). Biphasic effects of cannabinoids in anxiety responses: CB1 and GABA(B) receptors in the balance of GABAergic and glutamatergic neurotransmission. Neuro Psychopharmacology 37: 2624-2634.
95. Roohbakhsh A, Keshavarz S, Hasanein P, Rezvani ME, Moghaddam AH (2009). Role of endocannabinoid system in the ventral hippocampus of rats in the modulation of anxiety-like behaviours. Basic Clin Pharmacol Toxicol 105: 333-338.
96. Rubino T, Sala M, Viganò D, Braida D, Castiglioni C, Limonta V, et al. (2007). Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral delta9-Tetrahydrocannabinol in rats. Neuropsychopharmacology 32:2036-2045.
97. Rubino T, Realini N, Castiglioni C, Guidali C, Viganò D, Marras E, et al. (2008). Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 18:1292-1301.
98. Russo EB, Burnett A, Hall B, Parker KK (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30:1037-1043.
99. Rutkowska M, Jamontt J, Gliniak H (2006). Effects of cannabinoids on the anxietylike response in mice. Pharmacol Rep 58:200-206.
100. Scherma M, Medalie J, Fratta W, Vadivel SK, Makriyannis A, Piomelli D, et al. (2008). The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 54:129-140.
101. Scherma M, Justinov Z, Zanettini C, Panlilio LV, Mascia P, Fadda P, et al. (2012). The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats. Br J Pharmacol 165:2539-2548.
102. Sciolino NR, Zhou W, Hohmann AG (2011). Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-Arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 64:226-234.
103. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR (1994). The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 270:219-227.
104. Starowicz K, Nigam S, Di Marzo V (2007). Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 114:13-33.
105. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. (1995). 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215:89-97.
106. Thomas H (1996). A community survey of adverse effects of cannabis use. Drug Alcohol Depend 42:201-207.
107. Umathe SN, Manna SS, Utturwar KS, Jain NS (2009). Endocannabinoids mediate anxiolytic-like effect of acetaminophen via CB1 receptors. Prog Neuropsychopharmacol Biol Psychiatry 33:1191-1199.
108. Vaughan CW, Connor M, Bagley EE, Christie MJ (2000). Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 57:288-295.
109. Viveros MP, Marco EM, File SE (2005). Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81:331-342.
110. Wiskerke J, Irimia C, Cravatt BF, De Vries TJ, Schoffelmeer AN, Pattij T, Parsons LH (2012). Characterization of the effects of reuptake and hydrolysis inhibition on interstitial endocannabinoid levels in the brain: An in vivo microdialysis study. ACS Chem Neurosci 3:407-417.
111. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, et al. (2011). The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21:655-679.
112. Xi ZX, Peng XQ, Li X, Song R, Zhang HY, Liu QR, et al. (2011). Brain cannabinoid CB2 receptors modulate cocaine's actions in mice. Nat Neurosci 14: 1160-1166.
113. Xing J, Li J (2007). TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. J Neurophysiol 97: 503-511.